FDMT

FDMT is a pre-revenue, clinical-stage gene-therapy company, so the traditional fundamentals look ugly by design: -$140M net loss, -187% operating margin, -164% net margin, -$716M accumulated deficit, and -$109M operating cash burn in FY2025. The eye-catching $85.2M 'revenue' (up from a $37K base) is not product sales — the 10-K is explicit that the company 'has not generated any product revenue' — it is essentially the $85M upfront from the October 2025 Otsuka collaboration. So the 8.8x P/S is meaningless here; this is a binary clinical story, not an earnings/valuation story.

What makes it more than a lottery ticket is the late-stage de-risking. Lead asset 4D-150 (in-office, durable anti-VEGF gene therapy for wet AMD/DME) has two Phase 3 trials running: 4FRONT-1 completed enrollment in ~11 months, ahead of plan and overenrolled at >500 patients, with 52-week topline data due H1 2027, and 4FRONT-2 due H2 2027. The Phase 1/2 PRISM interim (Nov 2025) showed durable visual-acuity maintenance with no new intraocular inflammation out to ~3.5 years, and SPECTRA DME showed a 78% treatment-burden reduction — a clean safety and durability signal in the exact endpoints Phase 3 must hit. The Otsuka deal ($85M upfront, up to $335.5M milestones, tiered double-digit royalties, plus global development cost-sharing) both validates the asset and provides non-dilutive funding into the readouts, and FDA/EMA alignment on a single Phase 3 for DME lowers the regulatory bar.